Rachel Narozniak, MA

Articles

Duvelisib Tested in Rare Lymphoma Subtype

March 4th 2020

Investigators propose that a PI3K-δ,γ inhibitor currently indicated for the treatment of 3 hematologic malignancies may be a key to boosting response rates in peripheral T-cell lymphoma, a disease setting defined by poor prognoses.

Rapid Advances Change the Paradigm in Bladder Cancer

March 4th 2020

Arjun V. Balar, MD, discusses how immunotherapy options are helping to reduce reliance on platinum chemotherapy and cystectomy, as well as further efforts to engage the immune system in the fight against bladder cancer and other pathways toward greater treatment efficacy and quality of life for patients.

First-in-Class ADC Expands Portfolio of Precision Therapies in Bladder Cancer

February 28th 2020

Bradley McGregor, MD, discusses enfortumab vedotin-ejfv’s path to approval and its future potential in bladder cancer.

Patients With Digestive Disorders Are More Likely to Develop GI Toxicities on Immunotherapy

February 28th 2020

Patients with preexisting inflammatory bowel disease have a significantly higher risk of developing gastrointestinal adverse events during treatment with an immunotherapybased anticancer regimen than those without inflammatory bowel disease.

Coronavirus and Cancer: What Oncologists Need to Know

February 27th 2020

Infectious diseases are the second-leading cause of mortality in patients with cancer, whose immune systems are often compromised, so it is essential for providers to keep abreast of the latest developments in the management of coronavirus disease 2019.

Ongoing Studies May Clarify Role of ADCs in Gastric Cancer and CRC

February 20th 2020

The approval of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer is generating hopes that similar strategies also may be effective against HER2-expressing gastric and colorectal cancers, according to a panel of experts in gastrointestinal malignancies.

Investigators Test PARP Inhibitor in IDH-Mutant Solid Tumors

February 13th 2020

Investigators will challenge therapeutic convention by testing a PARP inhibitor instead of an IDH-targeted therapy in patients with metastatic IDH1/2-mutated glioma, cholangiocarcinoma, and other solid tumors that are refractory to standard treatment.

Inaugural HCT Guideline Focuses on Patient Selection, GVHD Treatment

February 4th 2020

In response to a rise in hematopoietic cell transplantation, the National Comprehensive Cancer Network has published its first guideline for the specialized intervention, which is performed approximately 22,000 times a year in the United States in patients with hematological cancers and other diseases.

Investigators Seek New Standard in RET Fusion–Positive NSCLC

February 4th 2020

Investigators hope selpercatinib (LOXO-292), a highly selective RET inhibitor, will demonstrate potential as a new standard of care for patients with advanced or metastatic treatment-naïve RET fusion–positive non–small cell lung cancer in the phase III LIBRETTO-431 (NCT04194944) trial.

Investigators Tackle Resistance, Poor Response in Metastatic Melanoma

January 31st 2020

Immune checkpoint inhibitors (ICIs) combined with the anti–CTLA-4 agent ipilimumab (Yervoy) have dramatically improved survival in metastatic melanoma, but resistance and lack of response remain obstacles to wider efficacy, Mario Sznol, MD, said in a presentation during the 4th Annual International Congress on Immunotherapies in Cancer®. Multiple efforts are under way to understand these issues better and develop improved biomarkers for response, Sznol added.

Real-World Study Shows High Rates of Endocrinopathies Are Linked to Immune Checkpoint Inhibitors

January 29th 2020

Use of immune checkpoint inhibitors correlates with high incidence of endocrinopathies, especially anti–CTLA-4 therapy.

Investigators Test Breakthrough-Designated Triplet in First-Line CRC

January 17th 2020

Investigators hope to answer a potentially paradigm-changing question in the phase II ANCHOR-CRC study (NCT03693170) of BRAF V600E–mutant colorectal cancer (CRC): Can the benefit observed with a targeted triplet in latestage disease extend to the first line?

Molecular Testing for Colon Cancer Falls Far Short of the Guidelines

January 16th 2020

Between 2013 and 2017, just 40% of patients with metastatic colon cancer received guideline-recommended biomarker testing that could have improved treatment decisions, according to findings from a retrospective study. Results also showed that adherence to evidence-based recommendations for genotyping was poor in academic and community settings alike.

SITC Poised to Expand Toolkit of Immunotherapy Guidelines

January 11th 2020

The Society for Immunotherapy of Cancer is developing a growing menu of guidelines with treatment algorithms for specific cancer types to help practicing oncologists navigate the appropriate use of this emerging modality.

Zanubrutinib Faces Off Against Ibrutinib in CLL Trial

January 8th 2020

Armed with the knowledge that inhibition of the Bruton tyrosine kinase is an effective approach in B-cell malignancies, investigators will explore the efficacy of the second-generation BTK inhibitor, zanubrutinib, in 2 leukemia and lymphoma subtypes.

Cardiac Therapy Improves Heart Function in Patients With Chemotherapy-Induced Events

January 4th 2020

Cardiac resynchronization therapy improved heart function in patients who developed chemotherapy-induced cardiomyopathy.

Investigators Test Tumor-Treating Fields in Lung Cancer

December 11th 2019

Investigators are attempting to advance the late-stage non–small cell lung cancer treatment paradigm by combining an emerging antimitotic modality with standard-of-care therapies in the phase III LUNAR trial.

Novel HER2-Targeted Agent May Improve Options in Recurrent Metastatic Breast Cancer

December 3rd 2019

In an effort to expand treatment options for patients with recurrent HER2-positive breast cancer, investigators are testing a novel antibody-drug conjugate: [fam-] trastuzumab deruxtecan (DS-8201a). The drug has achieved breakthrough therapy status.

ASTRO Presents First Guideline for RT in Pancreatic Cancer

November 30th 2019

Recent strides in systemic treatment approaches and the broader application of stereotactic radiation led the American Society for Radiation Oncology to issue its first guideline regarding radiation therapy in patients with pancreatic cancer.

Study Results Show Greater Hypertension, Cardiovascular Risks With Ibrutinib

November 29th 2019

Use of ibrutinib (Imbruvica) significantly increased the risk of early onset hypertension and was associated with long-term risk of developing other major cardiotoxic events in patients with B-cell malignancies.